Showing results (481-490 of 921) with videos related to
Sort By:
Pageof 93
Clinical and Experimental Immunology|July 2, 1998
The human autoantigen La/SS-B accelerates herpes simplex virus type 1 replication in transfected mouse 3T3 cellsM Bachmann, H Deister, A Pautz, et al.Sarcoma|June 4, 2008
Factors Influencing Prognosis After Initial Inadequate Excision (IIE) for Soft Tissue SarcomaAlbert N Van Geel, Alexander M M Eggermont, Patrick E J Hanssens, et al.American Journal of Respiratory and Critical Care Medicine|December 31, 1997
Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airwaysA R Sousa, B E Lams, R Pfister, et al.Drug and Alcohol Dependence|December 9, 2008
Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trialMarc E Mooney, David V Herin, Joy M Schmitz, et al.Frontiers in Psychiatry|September 13, 2012
Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary InvestigationJoy M Schmitz, Nuvan Rathnayaka, Charles E Green, et al.Journal of Substance Use and Addiction Treatment|April 26, 2026
Network intervention analysis of ACT processes in cocaine use disorderDuckhyun Jo, Elizabeth A Bodalski, Samuel J Leonard, et al.Anti-Cancer Drugs|November 5, 2003
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinomaCatharina Wenzel, Gottfried J Locker, Rupert Bartsch, et al.Breast (Edinburgh, Scotland)|February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerT Brodowicz, W J Kostler, R Möslinger, et al.The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.European Journal of Cancer (Oxford, England : 1990)|May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerI Lang, M J Inbar, Z Kahán, et al.Pageof 93